Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 12/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.58 |
| ▸ | LSS | P48449 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3153554 | 0.88 | SIGMAR1 (0.71) | CHRM3SIGMAR1NR1H2 | |
| SCHEMBL31612486 | 0.88 | SIGMAR1 (0.71) | CHRM3SIGMAR1NR1H2 | |
| SCHEMBL26124226 | 0.86 | CYP2D6 (0.67) | CHRM3SIGMAR1LSS | |
| SCHEMBL10669758 | 0.86 | LSS (0.62) | SIGMAR1LSSCRBNSLC2A1 | |
| SCHEMBL11606929 | 0.85 | CYP2D6 (0.70) | SIGMAR1LSS | |
| Hydrochloric Acid SCHEMBL30851239 | 0.84 | CXCR4 (0.62) | SIGMAR1LSSCRBNSLC2A1 | |
| SCHEMBL29478520 | 0.83 | SIGMAR1 (0.72) | CHRM3SIGMAR1 | |
| SCHEMBL1888148 | 0.83 | SIGMAR1 (0.72) | CHRM3SIGMAR1 | |
| SCHEMBL1632938 | 0.82 | PRMT6 (0.61) | CHRM3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL4819656 | 0.81 | SIGMAR1 (0.70) | CHRM3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | GLUETACS THERAPEUTICS SHANGHAI CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | CDR2, CYC1, CLN6 | CHRM3 484/4885SIGMAR1 345/4885LSS 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.